Radiopharm Theranostics Limited
Radiopharm Theranostics Limited (RADX): 7 pipeline candidates · 1 upcoming catalyst · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E 1.02 · 0% dilution
Lead: Phase 1/Phase 2
7 candidates
1 upcoming, next in ~12d
N/A
A transparent, data-derived signal for Radiopharm Theranostics Limitedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$34.8M
Cash
$29.1M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| 161tb rad402 | Phase 1/Phase 2 |
| 177lu-betabart | Phase 1/Phase 2 |
| 177lu-rad202 | Early Phase 1 |
| 177lu-rad204 | Early Phase 1 |
| lnth-2403 | Phase 1 |
| rad101 | Phase 2 |
| rad301 | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$1.3M
| Holder | Shares | Value |
|---|---|---|
| silverarc capital management, llc | 187,406 | $806K |
| hsbc holdings plc | 61,372 | $265K |
| regal partners ltd | 40,138 | $173K |
| pnc financial services group, inc. | 16,000 | $69K |
| rhumbline advisers | 121 | $519 |
Frequently asked questions
How many drug candidates are in Radiopharm Theranostics Limited's pipeline?
Radiopharm Theranostics Limited (RADX) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Radiopharm Theranostics Limited's lead drug candidate?
Radiopharm Theranostics Limited's most advanced tracked candidate is 161tb rad402 (Phase 1/Phase 2) for Castration-resistant Prostate Cancer.
What is Radiopharm Theranostics Limited's next catalyst?
Radiopharm Theranostics Limited's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: rad101" — expected June 30, 2026.
What is Radiopharm Theranostics Limited's market capitalization?
Radiopharm Theranostics Limited's market capitalization is approximately $34.8M.
Who is the CEO of Radiopharm Theranostics Limited?
Mr. Riccardo Canevari is the chief executive officer of Radiopharm Theranostics Limited (RADX).
Get the full picture on Radiopharm Theranostics Limited
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.